Insulin/weight ratio may serve as a predictor of success during insulin pump therapy in type 2 diabetes patients: a proof-of-concept study

Aims. To evaluate long-term efficacy of CSII for treating type 2 diabetes patients. To make an attempt to predict which patient would be more likely to reduce HbA1c levels (success) on CSII. Methods. 18 Type 2 diabetes patients who began insulin pump therapy in our institute were included. All pat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shmuel Levit, Yury Ivanovich Filippov, Ohad Cohen, Maria Weichman, Joseph Azuri, Yossi Manisteski, Vyacheslav Moiseevich Levit
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2015
Materias:	insulin weight obese pump type 2 diabetes concept Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/410d0d288b45450eb2e710d27366a10a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:410d0d288b45450eb2e710d27366a10a
record_format	dspace
spelling	oai:doaj.org-article:410d0d288b45450eb2e710d27366a10a2021-11-14T09:00:19ZInsulin/weight ratio may serve as a predictor of success during insulin pump therapy in type 2 diabetes patients: a proof-of-concept study2072-03512072-037810.14341/DM2015170-77https://doaj.org/article/410d0d288b45450eb2e710d27366a10a2015-03-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6755https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aims. To evaluate long-term efficacy of CSII for treating type 2 diabetes patients. To make an attempt to predict which patient would be more likely to reduce HbA1c levels (success) on CSII. Methods. 18 Type 2 diabetes patients who began insulin pump therapy in our institute were included. All patients were previously treated by insulin with a mean duration of 54.9?51.4 months. Results. Mean duration of follow-up with CSII was 42.2?27.0 months. No significant changes were seen in HbA1c in total cohort (p=0.064), but fasting plasma glucose was reduced from 10,5?2,9 to 7,6?1,9 mmol/l, p=0.007. No weight gain and no severe hypoglycemia were noted. All patients were divided to three groups according to their HbA1c levels: those whose treatment was successful (A), failed (B) or neutral (C), (5, 8, 5 patients respectively). A difference was found in insulin/weight (IWR) ratio within the group A: 0.81?0.29 U/kg before vs. 0.41 ?0.12 U/kg on CSII, p=0.043. There was a difference in IWR on CSII in group A compared to group B (0.41 ?0.12 U/kg vs. 0.93?0.6 U/kg respectively, p=0.011). We also noted a trend of weight reduction in the group A vs. weight gain in the group B. Conclusions. CSII is a viable tool in insulin ? requiring type 2 diabetes persons, since the insulin dosing and release it provides are much more physiological. CSII is safe and effective for improving glycemic control, but not in all diabetes patients. We suggest IWR reduction may serve as an early predictor of success on CSII. This work may serve as a "proof-of-concept" study, demonstrating once again the fundamental role of strict weight control in type 2 diabetes. More studies are needed to explore and confirm our experience.Shmuel LevitYury Ivanovich FilippovOhad CohenMaria WeichmanJoseph AzuriYossi ManisteskiVyacheslav Moiseevich LevitEndocrinology Research Centrearticleinsulinweightobesepumptype 2 diabetesconceptNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 18, Iss 1, Pp 70-77 (2015)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	insulin weight obese pump type 2 diabetes concept Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	insulin weight obese pump type 2 diabetes concept Nutritional diseases. Deficiency diseases RC620-627 Shmuel Levit Yury Ivanovich Filippov Ohad Cohen Maria Weichman Joseph Azuri Yossi Manisteski Vyacheslav Moiseevich Levit Insulin/weight ratio may serve as a predictor of success during insulin pump therapy in type 2 diabetes patients: a proof-of-concept study
description	Aims. To evaluate long-term efficacy of CSII for treating type 2 diabetes patients. To make an attempt to predict which patient would be more likely to reduce HbA1c levels (success) on CSII. Methods. 18 Type 2 diabetes patients who began insulin pump therapy in our institute were included. All patients were previously treated by insulin with a mean duration of 54.9?51.4 months. Results. Mean duration of follow-up with CSII was 42.2?27.0 months. No significant changes were seen in HbA1c in total cohort (p=0.064), but fasting plasma glucose was reduced from 10,5?2,9 to 7,6?1,9 mmol/l, p=0.007. No weight gain and no severe hypoglycemia were noted. All patients were divided to three groups according to their HbA1c levels: those whose treatment was successful (A), failed (B) or neutral (C), (5, 8, 5 patients respectively). A difference was found in insulin/weight (IWR) ratio within the group A: 0.81?0.29 U/kg before vs. 0.41 ?0.12 U/kg on CSII, p=0.043. There was a difference in IWR on CSII in group A compared to group B (0.41 ?0.12 U/kg vs. 0.93?0.6 U/kg respectively, p=0.011). We also noted a trend of weight reduction in the group A vs. weight gain in the group B. Conclusions. CSII is a viable tool in insulin ? requiring type 2 diabetes persons, since the insulin dosing and release it provides are much more physiological. CSII is safe and effective for improving glycemic control, but not in all diabetes patients. We suggest IWR reduction may serve as an early predictor of success on CSII. This work may serve as a "proof-of-concept" study, demonstrating once again the fundamental role of strict weight control in type 2 diabetes. More studies are needed to explore and confirm our experience.
format	article
author	Shmuel Levit Yury Ivanovich Filippov Ohad Cohen Maria Weichman Joseph Azuri Yossi Manisteski Vyacheslav Moiseevich Levit
author_facet	Shmuel Levit Yury Ivanovich Filippov Ohad Cohen Maria Weichman Joseph Azuri Yossi Manisteski Vyacheslav Moiseevich Levit
author_sort	Shmuel Levit
title	Insulin/weight ratio may serve as a predictor of success during insulin pump therapy in type 2 diabetes patients: a proof-of-concept study
title_short	Insulin/weight ratio may serve as a predictor of success during insulin pump therapy in type 2 diabetes patients: a proof-of-concept study
title_full	Insulin/weight ratio may serve as a predictor of success during insulin pump therapy in type 2 diabetes patients: a proof-of-concept study
title_fullStr	Insulin/weight ratio may serve as a predictor of success during insulin pump therapy in type 2 diabetes patients: a proof-of-concept study
title_full_unstemmed	Insulin/weight ratio may serve as a predictor of success during insulin pump therapy in type 2 diabetes patients: a proof-of-concept study
title_sort	insulin/weight ratio may serve as a predictor of success during insulin pump therapy in type 2 diabetes patients: a proof-of-concept study
publisher	Endocrinology Research Centre
publishDate	2015
url	https://doaj.org/article/410d0d288b45450eb2e710d27366a10a
work_keys_str_mv	AT shmuellevit insulinweightratiomayserveasapredictorofsuccessduringinsulinpumptherapyintype2diabetespatientsaproofofconceptstudy AT yuryivanovichfilippov insulinweightratiomayserveasapredictorofsuccessduringinsulinpumptherapyintype2diabetespatientsaproofofconceptstudy AT ohadcohen insulinweightratiomayserveasapredictorofsuccessduringinsulinpumptherapyintype2diabetespatientsaproofofconceptstudy AT mariaweichman insulinweightratiomayserveasapredictorofsuccessduringinsulinpumptherapyintype2diabetespatientsaproofofconceptstudy AT josephazuri insulinweightratiomayserveasapredictorofsuccessduringinsulinpumptherapyintype2diabetespatientsaproofofconceptstudy AT yossimanisteski insulinweightratiomayserveasapredictorofsuccessduringinsulinpumptherapyintype2diabetespatientsaproofofconceptstudy AT vyacheslavmoiseevichlevit insulinweightratiomayserveasapredictorofsuccessduringinsulinpumptherapyintype2diabetespatientsaproofofconceptstudy
_version_	1718429520736813056

Insulin/weight ratio may serve as a predictor of success during insulin pump therapy in type 2 diabetes patients: a proof-of-concept study

Ejemplares similares